MaxorPlus Formulary Update: Biosimilars
We are changing our formulary list for 2025, moving to a biosimilar for a frequently prescribed medication, Humira®. This switch […]
We are changing our formulary list for 2025, moving to a biosimilar for a frequently prescribed medication, Humira®. This switch […]
Dry eye disease (DED) is a common medical condition, and according to the National Eye Institute, it affects about 16
Maxor proudly announces that its pharmacy benefit management division, MaxorPlus, has been honored with the Top Workplaces 2024 award by
Introducing our Drug Pipeline Spotlight We’ve highlighted three groundbreaking drugs recently approved or pending approval from the FDA. Want to
The automated approach to optimizing 340B savings & patient care while overcoming manufacturer restrictions NOTE:Â The purpose of this article is
We want to extend a big thank you to all the healthcare workers who tirelessly dedicate themselves to the care
Many organizations fail to incorporate a holistic approach to pharmacy and typically will separate pharmacy benefit management from pharmacy operations
VytlOne has supported the 340B programs of more than 100 health systems and health centers since 2019. Altogether, we’ve generated
At Maxor, we take pride in our comprehensive approach to healthcare. Our pharmacy services, benefit management solutions, and specialty pharmacy
In this five-part blog series, we explore the top challenges community health centers face when running profitable, efficient, and impactful